FDA to publish MRA (mutual recognition agreement) expansion proposal "within weeks"
This article was originally published in Clinica
Executive Summary
The European Commission has welcomed the US FDA's proposal to significantly expand the list of products eligible for inclusion in the EU/US mutual recognition agreement (MRA) and to include in vitro diagnostic products. European industry has generally been unenthusiastic about the trade agreement because of the small number of devices (97) included and has long been pushing for a broader scope (see Clinica No 943, p 3).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.